May 11, 2017
ASF-funded Research Identifies Biomarker for Clinical Trials ASF-funded research published in the Journal of Neurodevelopmental Disorders has identified that delta—a frequency of brain rhythms identifiable by EEG scans—can serve as a reliable biomarker for pre-clinical and clinical trials in Angelman syndrome. The research team, […]
Read more
April 24, 2017
Stem Cells Help UConn Researchers Identify Defects Causing Angelman syndrome Researchers at UConn Health are using stem cells derived from patients with Angelman syndrome to identify the underlying cellular defects that cause the rare neurogenetic disorder, an important step in […]
Read more
September 9, 2016
Ovid Therapeutics, a privately held biopharmaceutical company based in New York City, announced that the U.S. Food and Drug Administration has granted orphan drug designation to OV101 for the treatment of patients with Angelman syndrome. See the press release.
Read more
April 20, 2016
Research has answered some questions about UBE3A’s role in seizures ASF-funded research conducted at Dr. Ben Philpot’s lab at the University of North Carolina-Chapel Hill has answered some questions about UBE3A’s role in seizures in individuals with Angelman syndrome, and […]
Read more
December 8, 2015
Research Investigates Health Issues in Adults with Angelman Syndrome Dr. Ron Thibert, the well-known Angelman syndrome clinician and champion of the low-glycemic index dietary seizure treatment, and Dr. Anna Larson, both of Massachusetts General Hospital, published the findings from their clinical […]
Read more
November 30, 2015
The ASF Celebrates the Opening of the New Angelman Syndrome Clinic at Mayo Clinic One-Stop Facility Provides Comprehensive Support for Individuals with Angelman syndrome from Infancy through Adulthood ROCHESTER, Minn., November 30, 2015 – Mayo Clinic and the Angelman Syndrome Foundation […]
Read more
August 6, 2015
Angelman Syndrome Foundation-Funded Research at University of North Carolina-Chapel Hill Leads to Breakthrough in AS- and Autism-related research Research from the lab of Dr. Mark Zylka, a leading AS researcher and associate professor of cell biology and physiology at the […]
Read more
April 20, 2015
Ovid is working with patients and families to develop failed drugs for rare and Orphan brain diseases, starting with Angelman syndrome . . .
Read more